Cargando…

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

OBJECTIVE: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation. The aim of this study was to evaluate the real-life impact of posaconazole prophylaxis. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özkocaman, Vildan, Özkalemkaş, Fahir, Seyhan, Serdar, Ener, Beyza, Ursavaş, Ahmet, Ersal, Tuba, Kazak, Esra, Demirdöğen, Ezgi, Mıstık, Reşit, Akalın, Halis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256813/ https://www.ncbi.nlm.nih.gov/pubmed/30047484 http://dx.doi.org/10.4274/tjh.2017.0430

Ejemplares similares

Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies
por: Gursoy, Vildan, et al.
Publicado: (2021)

Serum galactomannan levels in the diagnosis of invasive aspergillosis
por: Okuturlar, Yildiz, et al.
Publicado: (2015)

Evaluation of Using Empiric Glycopeptides in Accordance with the IDSA Guidelines in Hematologic Malignancy Patients with Febrile Neutropenia
por: Yalçın, Cumali, et al.
Publicado: (2022)

Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia
por: Ali, Ridvan, et al.
Publicado: (2006)

Tuberculosis presenting as immune thrombocytopenic purpura
por: Ozkalemkas, Fahir, et al.
Publicado: (2004)

The Role of White Blood Cell Count in Perianal Pathologies: A Retrospective Analysis of Hematologic Malignancies
por: Orhan, Bedrettin, et al.
Publicado: (2022)

Systemic inflammatory indices for predicting prognosis of myelofibrosis
por: Ersal, Tuba, et al.
Publicado: (2023)

Fatal Cryptococcal Meningitis in a Patient with Chronic Lymphocytic Leukemia
por: Dizdar, Oguzhan Sıtkı, et al.
Publicado: (2012)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: A clinical study of 19 cases
por: Ozkalemkas, Fahir, et al.
Publicado: (2005)

Trends of Bloodstream Infections in a University Hospital During 12 Years
por: Ülkü Tüzemen, Nazmiye, et al.
Publicado: (2022)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
por: Saglik, Imran, et al.
Publicado: (2022)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Can clinical factors be determinants of bone metastases in non-small cell lung cancer?
por: Ursavas, Ahmet, et al.
Publicado: (2007)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Comparison of Clinical Laboratory Standards Institute (CLSI) Microdilution Method and VITEK 2 Automated Antifungal Susceptibility System for the Determination of Antifungal Susceptibility of Candida Species
por: Dalyan Cilo, Burcu, et al.
Publicado: (2021)

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy
por: Sienkiewicz-Oleszkiewicz, Beata, et al.
Publicado: (2019)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization
por: Dilektasli, Asli Gorek, et al.
Publicado: (2017)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Long‐term oxygen treatment need is less frequent in eosinophilic COPD patients
por: Acet‐Öztürk, Nilüfer Aylin, et al.
Publicado: (2021)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Healthcare-Associated Stenotrophomonas maltophilia Bacteraemia: Retrospective Evaluation of Treatment and Outcome
por: Tuncel, Tekin, et al.
Publicado: (2021)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report
por: Mody, Mayur D., et al.
Publicado: (2017)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
por: Turkkan, Alpaslan, et al.
Publicado: (2022)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
por: Demirdöğen, Ezgi, et al.
Publicado: (2022)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis
por: Ozkan, Tanju Basarir, et al.
Publicado: (2007)

Diagnostic Efficacy of Aspergillus Galactomannan Lateral Flow Assay in Patients with Hematological Malignancies: A Prospective Multicenter Study
por: Alhan, Ozlem, et al.
Publicado: (2023)

Alginate Oligosaccharides Affect Mechanical Properties and Antifungal Activity of Alginate Buccal Films with Posaconazole
por: Szekalska, Marta, et al.
Publicado: (2019)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_klgfpdvb9s47gnkr47vo5k91sf